Corrigendum to "Structure guided development of potent piperazine-derived hydroxamic acid inhibitors targeting falcilysin" [Bioorg. Med. Chem. Lett. 32 (2021) 127683]

Affiliations

¹ Department of Chemistry and Biochemistry, California State University, San Bernardino, USA.
² Department of Chemistry and Biochemistry, California Polytechnic State University, San Luis Obispo, USA.
³ Department of Chemistry and Biochemistry, San Francisco State University, San Francisco, USA.
⁴ Campus Mass Spectrometry Facilities, University of California, Davis, USA.
⁵ Department of Chemistry and Biochemistry, California State University, San Bernardino, USA. Electronic address: jeremy.mallari@csusb.edu.

Free article

Published Erratum

Gulbag Kahlon et al. Bioorg Med Chem Lett. 2021.

Free article

. 2021 Apr 1:37:127836.

doi: 10.1016/j.bmcl.2021.127836. Epub 2021 Feb 13.

¹ Department of Chemistry and Biochemistry, California State University, San Bernardino, USA.
² Department of Chemistry and Biochemistry, California Polytechnic State University, San Luis Obispo, USA.
³ Department of Chemistry and Biochemistry, San Francisco State University, San Francisco, USA.
⁴ Campus Mass Spectrometry Facilities, University of California, Davis, USA.
⁵ Department of Chemistry and Biochemistry, California State University, San Bernardino, USA. Electronic address: jeremy.mallari@csusb.edu.

No abstract available

Erratum for

Structure guided development of potent piperazine-derived hydroxamic acid inhibitors targeting falcilysin.
Kahlon G, Lira R, Masvlov N, Pompa E, Brar N, Eagon S, Anderson MO, Andaya A, Chance JP, Fejzic H, Keniston A, Huynh N, Celis N, Vidal B, Trieu N, Rodriguez P, Mallari JP. Kahlon G, et al. Bioorg Med Chem Lett. 2021 Jan 15;32:127683. doi: 10.1016/j.bmcl.2020.127683. Epub 2020 Nov 20. Bioorg Med Chem Lett. 2021. PMID: 33227414